 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
This page provides links to speeches and testimony given by Commissioners and FTC staff concerning competition in health care markets.
2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 200 3| 2002 | 2001 | 2000 |1999 |1998 |1997 |1996 |1995 |1994 |1992 |
-
Prepared Statement of the Federal Trade Commission on Antitrust Enforcement in the Health Care Industry,
Presented by Richard A. Feinstein, Director, Bureau of Competition, Before the Subcommittee on Courts and Competition Policy of the Committee on the Judiciary, United States House of Representatives (December 1, 2010)
-
FTC Testifies: Stopping “Pay-for-Delay” Drug Settlement Agreements is a Top Competition Priority, Oversight of the Federal Trade Commission Bureau of Competition and the Department of Justice Antitrust Division,
Presented By Chairman Jon Leibowitz Before the Subcommittee on Courts and Competition Policy of the Committee on the Judiciary, United States House of Representatives (July 27, 2010) - “A Doctor and a Lawyer Walk into a Bar: Moving Beyond Stereotypes,”
Remarks by Chairman Jon Leibowitz as prepared for delivery, American Medical Association House of Delegates, Chicago, Illinois, June 14, 2010.
-
“Pay-for-Delay Settlements, Authorized Generics, and Follow-on Biologics: Thoughts on the How Competition Law Can Best Protect Consumer Welfare in the Pharmaceutical Context,” Presented by Commissioner Rosch at the World Generic Medicine Congress, Washington, D.C., November 19, 2009.
- Statement of FTC Chairman Jon Leibowitz on passage of H.R. 3126, the Consumer Financial Protection Act of 2009 by the House Energy and Commerce Committee
Remarks by Chairman Jon Leibowitz, October 29, 2009 - Statement of FTC Chairman Jon Leibowitz Senate Judiciary Committee’s Passage of the Preserve Access to Affordable Generics Act (S. 369)
Remarks by Chairman Jon Leibowitz, October 15, 2009 - A Healthcare Triptych
Remarks by Commissioner J. Thomas Rosch, September 23, 2009 FTC Watch - "The Importance of Competition and Antitrust Enforcement to Lower-Cost, Higher-Quality Health Care,"
Ttestimony before the Senate Subcommittee on Consumer Protection, Product Safety, and Insurance of the Committee on Commerce, Science & Transportation presented by Richard Feinstein, Director, Bureau of Competition, July 16, 2009. -
FTC Testifies in Support of Bill Banning “Pay-for-Delay” Settlements Between Brand and Generic Drug Companies
Congressional Action Needed to Prevent Higher Drug Costs to Consumers and Federal, State, and Local Governments - Prepared Statement of the Federal Trade Commission Before the Antitrust Task Force of the Committee on the Judiciary United States House of Representatives Concerning H.R. 971 “The Community Pharmacy Fairness Act of 2007”
Presented by Commissioner Jon Leibowitz Before the Center for American Progress, June 23, 2009 - Emerging Health Care Issues: Follow-on Biologic Drug Competition
Testimony Before the Subcommittee on Health Committee on Energy and Commerce United States House of Representatives, Commissioner Pamela Jones Harbour June 11, 2009 - Concurring Statement of Commissioner Jon Leibowitz
Federal Trade Commission v. Watson Pharmaceuticals et. al.
Presented by Commissioner Jon Leibowitz, February 2, 2009
-
Concurring Statement of Commissioner Jon Leibowitz Federal Trade Commission v. Ovation Pharmaceuticals, Inc.
Presented by Commissioner Jon Leibowitz, December 16, 2008 -
“Tales from the Crypt” Episodes ’08 and ’09: The Return of Section 5 (“Unfair Methods of Competition in Commerce are Hereby Declared Unlawful”) Remarks of Commissioner Leibowitz Section 5 Workshop October 17, 2008
Presented by Commissioner Jon Leibowitz at the FTC Section 5 Competition Statute Workshop, October 17, 2008 -
This Pill Not To Be Taken With Competition How Collusion Is Keeping Generic Drugs Off the Shelves
Remarks by Commissioner Jon Leibowitz, Washington Post Article, February 25, 2008 -
Statement of Commissioner Jon Leibowitz Concurring in Part and Dissenting in Part in the Matter of Cephalon, Inc.
Presented by Commissioner Jon Leibowitz, February 13, 2008
- Prepared Statement of the Federal Trade Commission Concerning "The Community Pharmacy Fairness Act of 2007"
Presented by David Wales, Deputy Director, Bureau of Competition, Before the Antitrust Task Force of the Committee on the Judiciary, United States House of Representatives (October 18, 2007)
-
The Role of Competition in Health Care Policy
Presented by Alden F. Abbott, Associate Director, Bureau of Competition, before the Mentor Group Central Europe Forum for Legal-Economic Affairs, Budapest, Hungary, July 10, 2007 -
Prepared Statement of the Federal Trade Commission On Protecting Consumer Access To Generic Drugs: The Benefits Of A Leglislative Solution To Anticompetitive Patent Settlements In The Pharmaceutical Industry
Presented by Commissioner Jon Leibowitz, Before the Subcommittee on Commerce, Trade, and Consumer Protection of the Committee On Energy and Commerce, United States House of Representatives (May 2, 2007). -
Prepared Statement of the Federal Trade Commission on American Innovation at Risk: The Case for Patent Reform
Presented by Suzanne Michel, Deputy Assistant Director for Policy and Coordination, Before the Subcommittee on Courts, the Internet, and Intellectual Property of the Committee on the Judiciary, United States House of Representatives, February 15, 2007
-
How Settlements Make Strange Bedfellows: Or How the Federal Trade Commission has Managed to Unite the Entire Pharmaceutical Industry (but only in Opposition to the FTC’s Position on Exclusion Payment Settlements)
Remarks by Commissioner Jon Leibowitz, September 29, 2006 -
Prepared Statement of the Federal Trade Commission on Consumer Protection and Competition Issues Concerning the Contact Lens Industry
Presented by Maureen Ohlhausen, Director, Office of Policy Planning, Before the Subcommittee on Commerce, Trade, and Consumer Protection of the Committee on Energy and Commerce, United States House of Representatives, September 15, 2006. - Prepared Statement of the Federal Trade Commission on Examining Competition in Group Health Care
Presented by David P. Wales, Deputy Director, Bureau of Competition, Before the Committee on the Judiciary of the United States Senate, September 6, 2006.
- Barriers to Generic Entry, Testimony before the U.S. Senate Special Committee on Aging,
Commissioner Jon Leibowitz, Commissioner, July 20, 2006.
- Exclusion Payments to Settle Pharmaceutical Patent Cases: They’re B-a-a-a-ck!
(The Role of the Commission, Congress, and the Courts)
Remarks by Commissioner Jon Leibowitz, Second Annual In-House Counsel’s Forum on
Pharmaceutical Antitrust, Philadelphia, PA, April 24, 2006.
- Health Care: An Interview with Commissioner Thomas B. Leary
This is an interview with Commissioner Leary conducted by the ABA Antitrust Section Health Care Committee Newsletter, published in the ABA's Antitrust Health Care Chronicle, October 2005, Vol. 19, No. 3.
- Prepared Statement of the Federal Trade Commission On New Entry Into Hospital Competition, Presented by John D. Graubert, Principal Deputy General Counsel of the Commission, Before the Subcommittee on Federal Financial Management, Government Information, and International Security of the Committee on Homeland Security and Governmental Affairs, United States Senate, May 24, 2005.
- Health Care and the FTC: The Agency as Prosecutor and Policy Wonk(Health Care as the New Cement; and Actions Against the Pharmaceutical Industry as a Game of Whack-a-Mole) Jon Leibowitz, Commissioner, Antitrust in HealthCare Conference, American Bar Association/American Health Lawyers Association, Washington, D.C., May 12, 2005
- A “Check-Up” of Selected Health Care Activity at the Federal Trade Commission
Pamela Jones Harbour, Commissioner, ABA Antitrust Section Spring Meeting “The Agencies’ 2004 Report on Improving Health Care: Comments on the Report and Its Aftermath”, March 30, 2005
- The Federal Trade Commission: Fostering a Competitive Health Care Environment That Benefits Patients
Deborah Platt Majoras, World Congress Leadership Summit, New York, NY, February 28, 2005
- Diagnosing Physician-Hospital Organizations
Susan A. Creighton, Remarks Before the American Health Lawyers Association, Program on Legal Issues Affecting Academic Medical Centers and Other Teaching Institutions, Washington, DC, January 22, 2004
-
Prepared Statement of the Federal Trade Commission Regarding the Senate and House of Representatives Versions of the "Greater Access to Affordable Pharmaceuticals Act,"
Presented by Chairman Timothy J. Muris Before the Committee on the Judiciary, United States Senate, August 1, 2003 - Competition In the Pharmaceutical Industry
Testimony before the Committee on Judiciary, United States Senate, Chairman Timothy J. Muris, June 17, 2003
- Special Challenges for Antitrust in Health Care
Thomas B. Leary, This article is a written version of a speech given at a forum on Antitrust and Health Care jointly sponsored by the Health Lawyers Association and the ABA Sections of Antitrust Law and Health Law (May 15, 2003), and is published in Antitrust, Spring 2004, Volume 18, No. 2, at 23.
- Everything Old is New Again: Health Care and Competition in the 21st Century
Timothy J. Muris, Prepared remarks before 7th Annual Competition in Health Care Forum, Chicago, Illinois, November 7, 2002
- Competition in the U.S. Pharmaceutical Industry, Testimony Before the Subcommittee on Health Chairman Timothy J. Muris, October 9, 2002.
- Anticompetitive Activities in the Pharmaceutical Industy, GphA Annual Meeting & Educational Conference and Fifth Annual IGPA Conference, R. Ted Cruz, April 9, 2002.
- Pharmaceutical Industry, Testimony before the Committee on Commerce, Science, and Transportation, Chairman Timothy J. Muris, April 23, 2002
- The Antitrust Implications of "Clinical Integration:" An Analysis of FTC Staff's Advisory Opinion to MedSouth, Saint Louis University Health Law Symposium, Commissioner Thomas B. Leary, April 12, 2002. (This speech is published in issue 47:2 of the Saint Louis University Law Journal, at page 217. )
- Competition in the Pharmaceutical Marketplace, Testimony before the Senate Judiciary Committee, Molly Boast, May 24, 2001.
- Antitrust Issues in the Settlement of Pharmaceutical Patent Disputes, Part II The American Bar Association Healthcare Program, in Washington, D.C., Commissioner Thomas B. Leary, May 17, 2001 (This speech is published in the December 2001 edition of the Journal of Health Law, Vol. 34, at 657)
- Antitrust Issues in Settlement of Pharmaceutical Patent Disputes,
Sixth Annual Health Care Antitrust Forum, Northwestern University School of Law, Chicago, IL, Commissioner Thomas B. Leary, November 3, 2000 (This speech is published in Vol. 14 of the Antitrust Health Care Chron., Winter 2000/2001 at 4)
- Riddles and Lessons from the Prescription Drug Wars: Antitrust Implications of Certain Types of Agreements Involving Intellectual Property , remarks presented before the ABA “Antitrust and Intellectual Property: The Crossroads” Program, San Francisco California, Commissioner Sheila F. Anthony, June 1, 2000.
- Prepared Statement of the Federal Trade Commission Concerning H.R. 1304 the "Quality Health-Care Coalition Act of 1999", Presented by Robert Pitofsky, Chairman, Federal Trade Commission before The Committee on the Judiciary, United States House of Representatives
- Prepared Statement of the Federal Trade Commission Concerning H.R. 4277, the "Quality Health-Care Coalition Act of 1998", Presented by Robert Pitofsky, Chairman, Federal Trade Commission before the Committee on the Judiciary, United States House of Representatives, Washington, D.C., July 29, 1998
- Antitrust Enforcement and Hospital Mergers: A Closer Look
Presented at the "First Friday Forum" of the Alliance for Health, Grand Rapids, Michigan, June 5, 1998
- Antitrust Issues Raised by Rural, Health Care Networks
Presented at a Meeting of the Network Development Grantees Sponsored by the Federal Office of Rural Health Policy February 20, 1998
- Health Care Mergers: Will We Get Efficiencies Claims Right? before St. Louis University School of law Conference on Antitrust and Health Care: Current Antitrust Issues for the Health Care Provider, St. Louis, Missouri, Debra A. Valentine, November 14, 1997.
- Government Enforcement and Guidance in Health Care Antitrust: Maintaining the Balance
Presented at the American Bar Association 1997 Annual Meeting, August 5, 1997
- Shared Risk Exception to the Anti-Kickback Statute
Statement to the Negotiated Rulemaking Committee on the Shared Risk Exception to the Anti-Kickback Statute, Washington, D.C., June 18, 1997
- Overview of the Advisory Opinion Process at the Federal Trade Commission
Presented at the National Health Lawyers Association/Antitrust in the Health Care Field Conference on February 13 and 14, 1997.
- Thoughts on 'Leveling the Playing Field' in Health Care Markets before the National Health Lawyers Association, Twentieth Annual Program on Antitrust in the Health Care Field, Washington, D.C., February 13, 1997
- Beyond the Health Care Policy Statements: Where Do We Go from Here? before the 30th Annual Antitrust Institute on Healthcare Antitrust Developments, Cleveland, Ohio, November 1, 1996
- Current Issues in Health Care Antitrust Enforcement at the Federal Trade Commission before the American Bar Association, Antitrust & Health Care: New Approaches and Challenges, Omni Royal Orleans, New Orleans, Louisiana, October 24, 1996
- Antitrust Analysis of Hospital Networks and Shared Services Arrangements before the American Hospital Association, Sixth Annual OGC/Allied Legal Counsel Seminar, New York, New York, October 10, 1996
- Reinventing Health Care Antitrust Enforcement before The Antitrust Common Ground Conference, Nashville, Tennessee, May 17, 1996
- Testimony of the Federal Trade Commission Concerning H.R. 2925, and the Application of the Antitrust Laws to Health Care Provider Networks before The Committee on the Judiciary, United States House of Representatives, Washington D.C., February 27, 1996
- Antitrust Issues in Integrated Health Care Delivery Systems before the "1996 Conference on Practice Management" Presented by the American Society of Anesthesiologists, New Orleans, Louisiana, January 13, 1996
- Antitrust, Medicare Reform and Health Care Competition before the American Enterprise Institute for Public Policy Research, Washington, D.C., December 5, 1995
- Health Care Antitrust Enforcement Issues before the Health Trustee Institute, Cleveland, Ohio, November 9, 1995
- The Health Care and Antitrust Interface in an Era of Fundamental, Industry-Wide Realignments
SMS Health Executives Forum, Naples, Florida, October 23, 1995
- The Dangers of Health Industry Consolidation and Corporatization and the Effect on Quality, Cost and Access before The Citizens Fund Conference, Drug Industry Panel, Washington, D.C., May 10, 1995
- New Directions at the FTC: Efficiency Justifications in Hospital Mergers and Vertical Integration Concerns before The Health Care Antitrust Forum, Chicago, Illinois, May 2, 1995
- Legislative Hearings on Healthcare Issues, V950001
BE staff testifies that Vermont health care proposal runs risk of raising prices for health care services (10/19/94)
- Hospitals and Competition Policy, American Protestant Health Association, Washington Leadership Forum, Washington, D.C., Mary L. Azcuenaga, May 11, 1992
|
||||